Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Fredag 22 November | 02:05:03 Europe / Stockholm

Svenska | English

Västra Hamnen Market Focus

Prenumeration

Xintela: Closing in on the first license agreement

2024-05-29 09:45:00

• Non-binding term sheet with EQGen Biomedical regarding EQSTEM
• The financial situation is still an issue
• We keep the fair value at SEK 1.30 per share

In connection with the Q1 report, Xintela announced a signed, non-binding term sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s veterinarian joint disease treatment. We expect details to be disclosed once EQGen Biomedical secures funding and the parties announce a license agreement.

We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share. The full report is available here.

Västra Hamnen Market Focus

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden